BridgeBio LLC
421 Kipling Street
Palo Alto
California
94301
United States
Tel: 650-391-9740
Website: http://bridgebio.com/
Email: info@bridgebio.com
About BridgeBio LLC
We focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. Our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting R&D with expert capabilities and placing them in a value maximizing corporate structure.
Hope through rigorous science.
61 articles with BridgeBio LLC
-
BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement
10/5/2020
Agreement Brings BridgeBio’s Clinical Development and Commercial Development Infrastructureto Bear Upon Eidos’Acoramidis, Creating Anticipated Value for Patients with ATTR and Investors
-
The transaction between BridgeBio and Eidos is expected to close in the first quarter of 2021.
-
BridgeBio Pharma to Host Virtual R&D Day on September 29, 2020
9/22/2020
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers, today announced that it will host its first R&D Day on Tuesday, September 29, at 8:30 am E.T. The virtual event will feature presentations from BridgeBio founder and CEO, Neil Kumar, Ph.D., senior scientists and physicians leading BridgeBio's drug discovery and development programs, and
-
BridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1 (ADH1)
9/21/2020
BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Calcilytix Therapeutics, Inc. announced today the initiation of a Phase 2 single-center study of encaleret (CLTX-305) in individuals with ADH1 conducted at the National Institutes of Health. ADH1 is a rare, inherited disease caused by gain-of-function mutations in the c
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sep 03, 2020
9/3/2020
BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on September 1, 2020, the compensation committee of BridgeBio’s board of directors granted 10 new employees options to purchase an aggregate of 18,231 shares of the Company’s common stock with a per share exercise price of $27.62 and restricted stock units for an aggregate of 19,915 shares of the Company’s common stock.
-
BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update
8/11/2020
-Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beginning of 2020 -Strategic collaboration with Perceptive Advisors-founded company LianBio expands BridgeBio’s global reach into China -Ended quarter with $840.9 million in cash, cash equivalents and marketable securities SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focu
-
BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio
8/11/2020
$26.5 million total near-term payments to BridgeBio, plus participation in long-term value creation of up to $505 million in milestone payments, tiered double-digit royalty payments and an equity interest in LianBio. BridgeBio CEO and founder Neil Kumar, Ph.D., has been appointed to LianBio’s board of directors. PALO ALTO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers
-
BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia
7/15/2020
BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with the investigational medicine infigratinib, an orally available small molecule, that targets the overactivity of fibroblast growth factor receptor 3 (FGFR3) in the PROPEL 2 Phase 2 clinical trial . Achondroplasia is the most common cause of disproportionate short stature.¹ “With preclinical evidence sh
-
BridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual Meeting
7/10/2020
BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing Phase 1/2 study of PTR-01 (BBP-589), an intravenously-administered recombinant collagen 7 protein replacement therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). The presentation will be made during the Society for Pediatric Dermatology’s (SPD) 45th Annual Meeting, to be held virtu
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 06, 2020
7/6/2020
BridgeBio Pharma, Inc. announced that on July 1, 2020, the compensation committee of BridgeBio’s board of directors granted eight employees options to purchase an aggregate of 7,120 shares of the Company’s common stock with a per share exercise price of $30.34 and restricted stock units for an aggregate of 15,134 shares of the Company’s common stock, including 1,610 performance-related restricted stock units.
-
BioSpace Movers & Shakers, June 26
6/26/2020
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers. -
BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors
6/24/2020
BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has added three new independent directors to its board: former Allergan CEO and biopharma deal-maker, Brent Saunders; genomics pioneer and entrepreneur, Randy Scott, Ph.D.; and renowned economist and BridgeBio co-founder, Andrew Lo, Ph.D. “We are privileged to welcome these world-class company builders, inn
-
BridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven Diseases
6/18/2020
BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has entered into a collaboration agreement with Johns Hopkins University to support the translation of academic innovations in genetically driven diseases with a goal of clinical development and potential commercialization to reach patients in need. “We are privileged to establish a framework for collaborat
-
BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases
6/18/2020
Partnership to Leverage University of Florida’s Research in Gene Therapy and BridgeBio’s Translational Expertise in Rare and Genetic Disease
-
BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
6/11/2020
BridgeBio Pharma, Inc. affiliate ML Bio Solutions announced that the first subject has been dosed in the Phase 1 clinical trial of BBP-418, an orally-administered small molecule therapy being evaluated for the treatment of limb girdle muscular dystrophy type 2i.
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 05, 2020
6/5/2020
BridgeBio Pharma, Inc. announced that on June 1, 2020, the compensation committee of BridgeBio’s board of directors granted nine employees options to purchase an aggregate of 55,517 shares of the Company’s common stock with a per share exercise price of $28.88 and restricted stock units for an aggregate of 19,532 shares of the Company’s common stock, including 607 performance-related restricted stock units.
-
BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program
5/29/2020
BridgeBio Pharma, Inc. affiliate QED Therapeutics announced that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QED’s oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma.
-
BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in AchondroplasiaData Accepted to ENDO 2020
5/11/2020
BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in vivo data from two studies support QED’s plans to evaluate a low dose of infigratinib as a treatment option for children with achondroplasia, the most common cause of disproportionate short stature. Data were accepted for presentation at the Endocrine Society's Annual Meeting (“ENDO 2020”), which was cancelled due to COVID-19, and the studies
-
BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference in May 14, 2020
5/6/2020
BridgeBio Pharma, Inc. announced that it will present at the Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 11 AM.